XVIVO is likely to enter 2025 with a modest quarter during a period of macro-economic worries. XVIVO benefits from strong structural growth drivers already later in 2025 and the exposure to macro-economic challenges are modest. We regard the recent share price pressure as an opportunity. We make a slight negative revision ahead of Q1 as XVIVO continues to invest in sustainable growth during 2025 ahead of substantial launch support.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/